Ctgf antibody clinical
WebSep 23, 2024 · Abnormal and excessive growth of mesangial cells is important in the pathophysiologic processes of diabetes-associated interstitial fibrosis and glomerulosclerosis, leading to diabetic nephropathy, which eventually turns into end-stage renal disease. Sauchinone, a biologically-active lignan isolated from aerial parts of … WebJun 6, 2012 · The mechanism by which CTGF enables persistent fibrosis upon stimulation by TGFβ has never been elucidated, due at least in part to the very complex …
Ctgf antibody clinical
Did you know?
WebApr 11, 2024 · Nevertheless, clinical observations have shown that CTGF expression in the sera and fibrotic liver tissues of CHB patients is upregulated. A strong correlation between CTGF with liver fibrosis has also been reported . HBX can induce CTGF expression and secretion in hepatocytes to stimulate HSC activation . Multiple regulatory mechanisms ... WebPamrevlumab, our proprietary fully human antibody, targets connective tissue growth factor (CTGF), the central mediator of tissue remodeling and fibrosis. Pamrevlumab represents a potential treatment for a broad array of fibrotic and proliferative disorders that affect organ systems throughout the body. Pamrevlumab is in Phase 3 clinical studies for the …
WebAug 6, 2024 · The efficacy of CTGF inhibition previously observed in a wide variety of animal models is now being evaluated in clinical trials. Therefore, CTGF appears to be a candidate therapeutic target for kidney disease. ... FG-3019, a human monoclonal antibody to CTGF, has been used in some animal models, including pulmonary fibrosis, peritoneal ... WebMar 22, 2024 · CTGF Antibody (E-5) is a mouse monoclonal IgG 2a κ CTGF antibody, cited in 70 publications, provided at 200 µg/ml. specific for an epitope mapping between …
WebAug 24, 2024 · CTGF, a protein localized in the extracellular matrix, is a driver of fibrotic tissue remodeling as a consequence of an aberrant wound healing process. WebThe CCN family presently consists of six members in human also known as: Cyr61 (Cystein rich 61), CTGF (Connective Tissue Growth Factor), Nov (Nephroblastoma …
WebMonoclonal Antibody for studying CTGF. Cited in 36 publications. Validated for Western Blotting, Immunofluorescence (Immunocytochemistry). Highly specific and rigorously validated in-house, CTGF (D8Z8U) Rabbit …
WebClinical Consumables & Raw Materials. Primary Antibodies. Secondary Antibodies. Tag and Loading Control Antibodies. Antibody Duos. matched antibody pairs ... Western blot analysis of extracts of HepG2 cells, using CTGF antibody (A11067) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution. cleaners del city okWebJun 22, 2006 · FibroGen, Inc., today announced the publication of two studies demonstrating that connective tissue growth factor (CTGF) plays a causative role in pancreatic cancer … cleaners definitionWebDec 7, 2024 · A particularly exciting paper, recently published in Lancet Respiratory Medicine (Richeldi et al. 2024), described the recently successful Phase II clinical trial, PRAISE, which was a randomised, double-blind, placebo-controlled trial of the anti-CCN2 antibody FG-3019 (pamrevlumab) in idiopathic pulmonary fibrosis (IPF) … cleaners dewsburyWebApr 30, 2024 · As of December 31, 2024, there were a total of 250 integrated projects, including 121 projects in pre-clinical development stage, 112 projects in early-phase (phase I and II) clinical development ... downtown eastham maWebCtgf Antibody, Anti-CTGF antibody produced in rabbit. Tested Applications: immunohistochemistry 1:20- 1:50, immunofluorescence 1-4μg/mL, immunoblotting None. … cleaners degreasersWebApr 8, 2016 · FG-3019 is a human anti-CTGF IgG1 monoclonal antibody currently under clinical investigation as a potential therapeutic for treatment of idiopathic pulmonary … cleaners denmark waWebJul 22, 2024 · Pamrevlumab, an anti-CTGF human monoclonal antibody, is advancing towards Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. cleaners delivery